Marker Historical Financial Ratios
| MRKR Stock | USD 1.33 0.04 2.92% |
Marker Therapeutics is lately reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 168 will help investors to properly organize and evaluate Marker Therapeutics financial condition quickly.
Marker |
About Marker Financial Ratios Analysis
Marker TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Marker Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Marker financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Marker Therapeutics history.
Marker Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Marker Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Marker Therapeutics sales, a figure that is much harder to manipulate than other Marker Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Marker Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Marker Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.At this time, Marker Therapeutics' Net Debt To EBITDA is relatively stable compared to the past year. As of 03/28/2025, Current Ratio is likely to grow to 5.26, while Free Cash Flow Yield is likely to drop (0.32).
| 2022 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.91 | 1.05 | 1.0 | Revenue Per Share | 1.08 | 0.34 | 0.23 |
Marker Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Marker Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Marker Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 146.12 | 58.54 | 2.47 | 14.63 | 16.83 | 15.99 | |
| Ptb Ratio | 2.49 | 1.65 | 1.13 | 3.45 | 3.1 | 3.26 | |
| Days Sales Outstanding | 96.2 | 782.38 | 0.0697 | 97.37 | 87.63 | 168.31 | |
| Book Value Per Share | 5.81 | 5.75 | 2.35 | 1.6 | 1.44 | 1.51 | |
| Stock Based Compensation To Revenue | 11.2 | 4.8 | 0.37 | 0.26 | 0.3 | 0.28 | |
| Pb Ratio | 2.49 | 1.65 | 1.13 | 3.45 | 3.1 | 3.26 | |
| Ev To Sales | 126.64 | 34.0 | 2.0 | 10.07 | 11.58 | 11.0 | |
| Free Cash Flow Per Share | (6.23) | (3.97) | (3.82) | (1.87) | (1.68) | (1.76) | |
| Roic | (0.72) | (0.7) | (1.1) | (1.04) | (0.93) | (0.98) | |
| Net Income Per Share | (6.06) | (5.47) | (3.58) | (1.59) | (1.43) | (1.51) | |
| Payables Turnover | 6.43 | 0.61 | 3.34 | 10.84 | 12.47 | 14.2 | |
| Sales General And Administrative To Revenue | 22.43 | 10.41 | 1.42 | 2.26 | 2.6 | 2.47 | |
| Research And Ddevelopement To Revenue | 40.45 | 22.38 | 2.9 | 3.15 | 3.62 | 3.44 | |
| Capex To Revenue | 1.76 | 22.34 | 2.52 | 0.55 | 0.49 | 0.47 | |
| Cash Per Share | 4.54 | 5.54 | 1.41 | 1.72 | 1.97 | 1.87 | |
| Pocfratio | (3.62) | (2.66) | (0.82) | (2.95) | (3.39) | (3.22) | |
| Capex To Operating Cash Flow | (0.0205) | (0.55) | (0.11) | (0.18) | (0.21) | (0.2) | |
| Pfcf Ratio | (2.33) | (2.39) | (0.7) | (2.95) | (3.39) | (3.22) | |
| Days Payables Outstanding | 56.74 | 593.67 | 109.19 | 33.67 | 38.72 | 36.79 | |
| Roe | (1.04) | (0.95) | (1.53) | (1.0) | (1.15) | (1.09) | |
| Ev To Operating Cash Flow | (3.13) | (1.55) | (0.67) | (2.03) | (2.33) | (2.22) | |
| Pe Ratio | (2.39) | (1.74) | (0.74) | (3.45) | (3.1) | (3.26) | |
| Return On Tangible Assets | (0.63) | (0.61) | (0.87) | (0.82) | (0.74) | (0.77) | |
| Ev To Free Cash Flow | (2.02) | (1.39) | (0.57) | (2.03) | (2.33) | (2.22) | |
| Earnings Yield | (0.15) | (0.42) | (0.58) | (1.35) | (0.26) | (0.27) | |
| Net Debt To E B I T D A | 0.33 | 0.84 | 0.21 | 1.28 | 1.15 | 1.21 | |
| Current Ratio | 3.81 | 3.56 | 2.14 | 5.57 | 5.01 | 5.26 | |
| Tangible Book Value Per Share | 5.81 | 5.75 | 2.35 | 1.6 | 1.44 | 1.51 | |
| Receivables Turnover | 3.79 | 0.47 | 5.2K | 3.75 | 3.37 | 3.21 | |
| Shareholders Equity Per Share | 5.81 | 5.75 | 2.35 | 1.6 | 1.44 | 1.51 | |
| Capex Per Share | 0.0823 | 2.22 | 0.41 | 0.59 | 0.68 | 0.65 |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.